MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

ceftriaxone

  • Home
  • ceftriaxone
Ceftriaxone Resistance in Neisseria gonorrhoeae: Alarming Trends from the 2023 WHO EGASP Surveillance Report
Posted inInfectious Diseases news Public Health

Ceftriaxone Resistance in Neisseria gonorrhoeae: Alarming Trends from the 2023 WHO EGASP Surveillance Report

Posted by By MedXY 01/07/2026
The 2023 WHO EGASP study highlights a critical rise in ceftriaxone-resistant gonorrhea in Southeast Asia, with resistance reaching 20% in some regions. These findings underscore the urgent need for enhanced global surveillance and the accelerated development of novel antimicrobial therapies.
Read More
Oral Regimens for Whipple’s Disease: A Non-Inferiority Trial of Doxycycline-Hydroxychloroquine Versus Standard Intravenous Therapy
Posted inClinical Updates news Rheumatology Specialties

Oral Regimens for Whipple’s Disease: A Non-Inferiority Trial of Doxycycline-Hydroxychloroquine Versus Standard Intravenous Therapy

Posted by By MedXY 08/03/2025
A German phase 2/3 trial found oral doxycycline-hydroxychloroquine as effective and safe as standard intravenous ceftriaxone followed by oral trimethoprim-sulfamethoxazole for Whipple’s disease, potentially transforming outpatient management.
Read More
  • NF-κB Driven Transcriptional Signatures in CAR-T Cells Predict Durable Responses in Multiple Myeloma
  • Refining Right Ventricular Assessment in Pulmonary Hypertension: Impact of Postprocessing Techniques on Cardiac MRI Metrics
  • Decoding Persistent Tachypnea of Infancy: Genetic Insights Expand Diagnostic Paradigms
  • Mechanical Ventilation-Induced Neutrophil Extracellular Vesicles: A Novel Mediator in Postoperative Pulmonary Complications
  • Blood Transcriptomic Signatures as Predictors of Poor Outcomes in Drug-Susceptible Pulmonary Tuberculosis: Insights from a Brazilian Cohort
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification semaglutide SGLT2 inhibitors stroke type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top